Spero Therapeutics
SPRO
35 hedge funds and large institutions have $110M invested in Spero Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 7 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
20% more capital invested
Capital invested by funds: $91.2M → $110M (+$18.6M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.38% less ownership
Funds ownership: 53.99% → 53.62% (-0.38%)
5% less funds holding
Funds holding: 37 → 35 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.09M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$795K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$663K |
| 4 |
State Street
Boston,
Massachusetts
|
+$384K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$298K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.87M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$365K |
| 3 |
LCM
Laurion Capital Management
New York
|
-$170K |
| 4 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$118K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$103K |
SPRO Hedge Fund Activity: Q1 2018 in Review
35 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2018, worth a combined $110M — up 20% from $91.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SPRO and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 11 added.
The largest buyer was JP Morgan Chase, adding an estimated $3.09M. The largest seller was RA Capital Management, cutting an estimated $5.87M.
- 35 institutional investors held Spero Therapeutics (SPRO) as of Q1 2018, down from 37 in Q4 2017.
- Funds reported $110M of Spero Therapeutics stock for Q1 2018, up 20% quarter-over-quarter.
- 5 funds opened new Spero Therapeutics positions in Q1 2018 and 7 closed out, a net change of -2 holders.
- The largest Spero Therapeutics buyer in Q1 2018 was JP Morgan Chase, an estimated $3.09M added.
- The largest Spero Therapeutics seller in Q1 2018 was RA Capital Management, an estimated $5.87M sold.
Based on aggregated 13F filings for Q1 2018.